



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
 United States Patent and Trademark Office
 Address: COMMISSIONER FOR PATENTS
 P.O. Box 1450
 Alexandria, Virginia 22313-1450
 www.uspto.gov

BIB DATA SHEET

CONFIRMATION NO. 3995

SERIAL NUMBER	FILING or 371(c) DATE RULE	CLASS	GROUP ART UNIT	ATTORNEY DOCKET NO.
10/502,180		514	1612	OP/4-32328A

APPLICANTS

Romulus Kimbro Brazzell, Alpharetta, GA;
 George N. Lambrou, Strasbourg, FRANCE;
 Elisabeth Latour, Bartenheim-La Chaussee, FRANCE;
 Anna Ottlecz, Basel, SWITZERLAND;
 Jeanette Marjorie Wood, Benken, SWITZERLAND;

** CONTINUING DATA *****

This application is a 371 of PCT/EP03/00612 01/22/2003

** FOREIGN APPLICATIONS *****

UNITED KINGDOM 0201520.4 01/23/2002

** IF REQUIRED, FOREIGN FILING LICENSE GRANTED **

Foreign Priority claimed	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No	<input type="checkbox"/> Met after Allowance	STATE OR COUNTRY	SHEETS DRAWINGS	TOTAL CLAIMS	INDEPENDENT CLAIMS
35 USC 119(a-d) conditions met	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No					
Verified and Acknowledged	/GIGI GEORGIANA HUANG/ Examiner's Signature	Initials	GA	0	12	2

ADDRESS

NOVARTIS
 CORPORATE INTELLECTUAL PROPERTY
 ONE HEALTH PLAZA 104/3
 EAST HANOVER, NJ 07936-1080
 UNITED STATES

TITLE

Pharmaceutical use of cox-2-inhibitors in angiogenesis-mediated ocular disorders

FILING FEE RECEIVED 920	FEES: Authority has been given in Paper No. _____ to charge/credit DEPOSIT ACCOUNT No. _____ for following:	<input type="checkbox"/> All Fees
		<input type="checkbox"/> 1.16 Fees (Filing)
		<input type="checkbox"/> 1.17 Fees (Processing Ext. of time)
		<input type="checkbox"/> 1.18 Fees (Issue)
		<input type="checkbox"/> Other _____
		<input type="checkbox"/> Credit